Cytek Biosciences, Inc.
NASDAQCytek Biosciences heads into the final stretch of August with short sellers quietly retreating, the borrow market extraordinarily relaxed, and the next earnings date already fixed for November — leaving the stock to trade on analyst conviction and a sector tailwind that has broadly lifted life-science tools names this week. The short position has been unwinding steadily. Short…
CTKB short interest plunged 47% over the past week to 2.77% of float, down from elevated levels in early July as shares to borrow surged to 4,321% of estimated shorts—indicating minimal pressure for further covering.
Snapshot as of 26 Sept 2026
Cytek Biosciences heads into the final stretch of August with short sellers quietly retreating, the borrow market extraordinarily relaxed, and the next earnings date already fixed for November — leaving the stock to…
Cytek Biosciences enters the week after Q1 results fighting a 15% price drop, fresh target cuts from two analysts, and a short base that remains stubbornly elevated. The stock closed at $4.04 on Tuesday, down from…
Cytek Biosciences enters its post-earnings stretch on the back foot. Q1 EPS came in at -$0.15, missing the -$0.10 consensus by 50%, while revenue of $44.1M also fell short of estimates — and the stock gapped down 6.7%…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CTKB — free to start on ORTEX.
Sign up for free →Open CTKB on ORTEX